Latest filing published 29 Mar 2024 for Outlook Therapeutics, Inc., €21k.
Filing timeline
BuySaleInsider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Yezan Munther Haddadin: trading record in brief
Yezan Munther Haddadin, listed as board member, appears in our data through filings on Outlook Therapeutics, Inc. shares, published by SEC (Form 4). We count 6 filings; the first trade dates from 22 September 2020 and the latest from 28 March 2024.
Purchases make up the whole of the open-market record (6 purchases, €98k). Unlike grants, an open-market purchase is paid for by the insider, at the market price. 2024 to date brings 1 purchase and no sales.
The median purchase comes to €14k. 6 out of 6 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The record was last updated on 29 March 2024 with an open-market purchase (€21k) in Outlook Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Yezan Munther Haddadin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,881.711 shares@ US$11.8224.4% of flowCommon StockSEC:0001415889-24-009394:0Canonical exit: 26 Jun 2024 (T+90)
- 29,743 shares@ US$1.2946.5% of flowCommon StockSEC:0001209191-22-053354:0Canonical exit: 4 Jan 2023 (T+90)
- 10,000 shares@ US$1.3917.0% of flowCommon StockSEC:0001209191-21-067650:0Canonical exit: 2 Mar 2022 (T+90)
3 of 3 declarations